Answers are grounded in this paper and cite their sources.
Cerebral ischemia-reperfusion injury (CIRI) is a key pathological process underlying secondary neurological damage after ischemic stroke, yet the dynamic behavior of butyrylcholinesterase (BChE) during CIRI remains poorly understood. To address this unmet need, we engineered DCI2F-B, an activatable proximity-labeling far-red fluorogenic probe that integrated a cyclopropyl ester BChE-responsive unit with a difluoromethyl anchoring moiety. BChE-mediated hydrolysis triggered fluorescence activation at 640 nm with in situ anchoring, effectively minimizing signal diffusion that plagued conventional activatable probes. DCI2F-B exhibited high selectivity, approximately 33-fold fluorescence enhancement, and a detection limit of 0.02 U/mL. Using DCI2F-B, we visualized BChE upregulation in both oxygen-glucose deprivation/reoxygenation (OGD/R)-treated PC12 cells and middle cerebral artery occlusion/reperfusion (MCAO/R) mouse brains and monitored the neuroprotective response to quercetin. These results provided direct in vivo imaging evidence linking BChE upregulation to CIRI pathology, establishing DCI2F-B as an effective tool for BChE detection and CIRI assessment.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: